Expert Guidance for Optimizing Immune Checkpoint Inhibitor Therapy for Kidney and Bladder Cancer

Review these downloadable slides to gain expert perspective and current guideline recommendations for using immune checkpoint inhibitors for patients with urothelial cell or renal cell carcinoma. Faculty, Elizabeth R. Plimack, MD, MS; Timothy M. Kuzel, MD, FACP; and M. Dror Michaelson, MD, PhD, explain the current clinical rational and use of these immunotherapy options. Click here to use our online tool to see how to manage immune related AEs.

Downloadable Slidesets

In this downloadable slideset, Elizabeth R. Plimack, MD, MS, presents slides discussing the rationale for the use of immune checkpoint inhibitors for treating advanced urothelial cell and renal cell carcinoma.

Released: February 21, 2017

In this downloadable slideset, Timothy M. Kuzel, MD, FACP, presents slides discussing the data and clinical guidelines on the optimal use of immune checkpoint inhibitors for treating advanced urothelial cell carcinoma.

Released: February 21, 2017

In this downloadable slideset, M. Dror Michaelson, MD, PhD, presents slides discussing the data and clinical guidelines on the optimal use of immune checkpoint inhibitors for treating advanced renal cell carcinoma.

Released: February 21, 2017

In this downloadable slideset, Elizabeth R. Plimack, MD, MS, presents slides discussing the management of adverse events associated with immune checkpoint inhibitors for optimal outcomes in patients with advanced urothelial cell and renal cell carcinoma.

Released: February 21, 2017
Jointly sponsored by the National Comprehensive Cancer Network (NCCN) and Clinical Care Options, LLC.
NCCN Logo

Karen Kanefield
Manager CE Accreditation & Program Operations
National Comprehensive Cancer Network
3025 Chemical Road, Suite 100
Plymouth Meeting, PA 19462

215-690-0239
215-690-0283 (Fax)
gianola@nccn.org
For Clinicians:
NCCN.org
For Patients:
NCCN.org/patients

This activity is supported by an independent medical education grant from
AstraZeneca
Bristol-Myers Squibb
Genentech
Merck & Co., Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?